| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Xentuzumab | BI-836845 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Dusigitumab | MEDI-573 | Phase 2 Clinical | Medimmune Llc | Solid tumours; Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular | Details |

BettinastraBe 30, 60325 Frankfurt am Main



